Detailed explanation of the instructions and medication precautions for Avatrombopag (Su Kexin)

Avatrombopag (Avatrombopag) is a new oral thrombopoietin receptor agonist. It mainly promotes the differentiation and proliferation of bone marrow megakaryocytes by activating the thrombopoietin receptor (TPO-R), thereby increasing platelet production. The drug is mainly used clinically for patients with chronic liver disease who require invasive procedures due to thrombocytopenia, as well as for severe thrombocytopenia caused by specific hematological diseases. The research and development goals of avatrombopag are to reduce patients' need for blood transfusions, improve the safety of surgery and treatment, while reducing the risk of bleeding caused by thrombocytopenia, and provide a safer and more effective platelet management solution for clinical use.

According to the latest instructions, avatrombopag is an oral tablet, and the recommended starting dose needs to be adjusted based on the patient's platelet level and underlying disease. In patients with chronic liver disease, medication is usually started 5 to 10 days before invasive surgery so that platelet levels reach a safe range before surgery. Drug dosage and treatment duration should follow the principle of individualization and be adjusted based on treatment response and platelet monitoring results. It is generally recommended to take the tablet orally once daily, swallowing the whole tablet, with a meal or on an empty stomach, but use with a diet that contains alcohol or strong medications should be avoided.

Platelet counts need to be monitored closely during use of avatrombopag, especially during treatment initiation and dose adjustment. When a patient's platelet count rises too fast or exceeds the safe upper limit, medication should be suspended immediately or the dosage should be adjusted to prevent serious adverse events such as thrombosis. In addition, patients should undergo regular blood routine, liver function and renal function tests during treatment to detect potential toxicity or complications in a timely manner. When used in combination with other blood preparations or anticoagulant drugs, the risk of bleeding and thrombosis should be fully assessed, and the plan should be adjusted under the guidance of a doctor.

In clinical practice, common adverse reactions of avatrombopag include mild to moderate headache, fatigue, gastrointestinal discomfort, and mild platelet elevation. Although serious adverse reactions are rare, you still need to be alert to thrombotic events, liver function abnormalities and allergic reactions. Pregnant and lactating women, patients with severe liver function impairment, or patients who are allergic to avatrombopag ingredients must be strictly prohibited or used with caution. In terms of drug storage, it should be placed in a dry, cool, and dark environment to prevent children from accidentally taking it. In general, avatrombopag is a safe and effective thrombopoietin receptor agonist and is widely used in clinical applications. However, the instructions must be strictly followed during use, combined with individualized platelet monitoring and potential risk assessment, to ensure patient efficacy and safety.

Reference materials:https://www.drugs.com/